Kymriah Poised For Expansion In Follicular Lymphoma, Leveling The Field With Yescarta

Novartis will present data from the pivotal Phase II ELARA trial of the CAR-T therapy in relapsed/refractory follicular lymphoma at ASCO.

chess board — Kymriah aims to keep a level board with Yescarta • Source: Alamy

Novartis AG's Kymriah (tisagenlecleucel) is on track for a regulatory filing in an expanded indication – relapsed/refractory follicular lymphoma – that would give the CD19-targeting CAR-T therapy a similar indication to one already granted to Gilead Sciences, Inc.'s rival product, Yescarta (axicabtagene ciloleucel).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

21 Apr 2025

• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

21 Apr 2025

• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Oncology’s Most Eligible Unpartnered Assets

18 Apr 2025

• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

17 Apr 2025

• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.